–(BUSINESS WIRE)–Incyte is a global biopharmaceutical company focused on the discovery,
development and commercialization of novel medicines to meet serious
unmet medical needs. Incyte is committed to improving the lives of
patients, making a difference in healthcare and building sustainable
value for its stakeholders through scientific discovery.
The Company strives to discover and develop first-in-class and best-in
class medicines, and is advancing a broad and diversified selection of
clinical candidates in its growing portfolio of medicines in oncology
and inflammation and auto-immunity—the majority of which were discovered
at Incyte, by Incyte scientists. The breadth of Incyte’s portfolio and
its balance between early and later-stage product candidates is unique
for a company of its size.
Headquartered in Wilmington, Delaware, Incyte has operations in the
U.S., Europe and Japan, with a total of 13 offices worldwide and over
1,300 employees, including 600 world-class scientists who are leading
the field of biopharmaceutical research. For more information about
Incyte, visit www.incyte.com.
|Headquarters Address:||1815 Augustine Cutoff|
|Wilmington, DE 19803|
|Type of Organization:||Public|
|Key Executives:||CEO: Hervé Hoppenot|